Pseudomyxoma peritonei: Current chemotherapy and the need for mucin-directed strategies

Afshin Amini, Samar Masoumi-Moghaddam, David Lawson Morris

Research output: Contribution to journalReview ArticleResearchpeer-review

1 Citation (Scopus)


Introduction: Pseudomyxoma peritonei (PMP) is a rare neoplastic disease characterized by dissemination of mucinous tumor implants and accumulation of mucin in the abdominopelvic cavity. PMP is a progressive, recurrent condition that dramatically impacts quality of life. The current standard of care includes cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).Areas covered: The clinicopathological features of PMP closely correspond with multifocal distribution of mucin-secreting tumors and mucin collections. Hence, maximal elimination of all gross disease is attempted in the treatment of PMP. However, PMP is progressive and recurrent. In this review, current chemotherapy for PMP and a number of experimental strategies for enhancement of microscopic cytoreduction are addressed.Expert opinion: According to the current standard of care, HIPEC is the chemotherapy of choice for patients with PMP, which is delivered after completion of CRS. This multimodal approach offers long-term benefits for selected patients. Nevertheless, HIPEC fails to maintain the surgical complete response achieved by CRS and needs to be supplemented by novel strategies. Given the role of mucin and mucin-secreting cells in the pathophysiology of PMP, locoregional use of safe agents capable of inducing cytotoxic effects on residual tumor cells and eliminating mucin is a promising avenue for further investigation.

Original languageEnglish
Pages (from-to)183-193
Number of pages11
JournalExpert Opinion on Orphan Drugs
Issue number2
Publication statusPublished - 1 Feb 2015
Externally publishedYes


  • Chemotherapy
  • Hyperthermic intraperitoneal chemotherapy
  • MUC2
  • Mucin
  • Pseudomyxoma peritonei

Cite this